Actal is primarily used for the management of conditions characterized by acid-related stomach discomfort. The main clinical use of this medicine is in the temporary relief of symptoms associated with active duodenal ulcer. It is also indicated for the maintenance of healing in patients who have recovered from acute duodenal ulcers. These therapeutic domains involve providing local protection to the gastrointestinal lining.

Patients may find that the use of this medicine assists in addressing painful symptoms related to the digestive tract. Actal is used for the short-term treatment of active duodenal ulcer, and for maintenance therapy following healing.

Quick Fact: Relief for Stomach and Duodenal Ulcer Symptoms

Eligibility Map: Official Regulatory Information

The eligibility profile for Actal (Alexitol sodium) is defined primarily by specific restrictions and exclusions rather than absolute contraindications.

Category	Regulatory Status
Populations for whom use is contraindicated	The official regulatory document states there are no known contraindications.
Age-related eligibility rules	The medicine is not suitable for children under 12 years of age.
Populations for whom use is allowed	Adults and Elderly are included as eligible populations in the approved regulatory guidelines.

---

Condition-Specific Restrictions

Official labeling mandates careful consideration and special warnings for the following groups:

• Pregnancy: Use in pregnant patients requires careful consideration, as regulatory documents state there is inadequate evidence of safety in human pregnancy, especially during the first trimester.
• Renal Impairment: Patients with impaired kidney function are subject to caution for prolonged use due to the potential for aluminum accumulation, which the kidney normally eliminates.
• Metabolic Risk: Individuals on a low phosphate diet or those with malnutrition are restricted by a regulatory warning concerning the risk of phosphate depletion syndrome due to the aluminum component.

Interactions with Other Medicines and Products

The interaction profile for Actal, containing the antacid Alexitol sodium, is officially documented as primarily involving pharmacokinetic interference and cautions related to its aluminum component. This antacid's mechanism of raising gastric pH and the presence of aluminum cations can significantly reduce the systemic exposure of certain co-administered oral medicines.

Documented Interaction Patterns

Interaction Type	Interacting Substances/Conditions
Exposure Reduction	Tetracycline and Fluoroquinolone antibiotics, Levothyroxine, Iron salts, Bisphosphonates, and Salicylates (via altered excretion).
Increased Aluminum Exposure	Citrate-containing foods or supplements.
Population-Specific Caution	Renal Impairment, particularly when co-administered with citrate.

Regulatory Constraints

To prevent a significant and undesirable decrease in the plasma concentrations of susceptible drugs, regulatory guidance mandates a timing-separation rule. Administration of Alexitol sodium must be separated by an interval of at least two to four hours from the interacting oral medicine. The interaction with citrate is officially noted because it increases the systemic absorption of aluminum, which heightens the risk of accumulation for patients with impaired renal clearance.

Direct Chemical Buffering of Gastric Protons

The core mechanism of Alexitol sodium is a direct, non-systemic chemical reaction with Hydrogen ions ( H^+), the component of hydrochloric acid ( HCl) in the stomach lumen. The compound acts as a buffering agent, rapidly consuming these H^+ ions. This swift, local neutralization modifies the gastric pH homeostasis, resulting in a reduction of the fluid's chemical irritancy to the mucosal surface.

---

Functional Inactivation of Proteolytic Enzymes

The rapid pH increase triggered by the chemical buffering initiates a key physiological cascade: the functional inactivation of Pepsin. This digestive enzyme requires a highly acidic environment for its proteolytic activity. By elevating the pH above the optimal range, Alexitol sodium halts Pepsin's corrosive action, thereby contributing to the preservation of the epithelial environment. This non-receptor-mediated sequence decreases the destructive chemical potential of the stomach fluid on the exposed epithelial lining.

---

Non-Systemic Action and Mechanistic Limitations

The drug's action is strictly local and transient, confined entirely to the gastrointestinal tract. Unlike anti-secretory agents, Alexitol sodium does not inhibit the cellular mechanisms (like the proton pump) responsible for producing new acid. Its efficacy relies on the presence of existing HCl and is constrained by the stomach's continuous secretory activity, resulting in a temporary duration of the localized pH alteration.

How to Use Actal: Administration Guidelines

Actal, which contains the active ingredient Alexitol sodium, is used following established administration methods and dose limitations. As an antacid, its administration is designed to facilitate quick, localized action within the gastrointestinal tract, ensuring the compound's function is initiated rapidly.

---

Administration Scope

Feature	Guideline
Route of administration	Oral administration only.
Dosing schedule (Adults)	Standard single dose is two 360 mg tablets (720 mg).
Frequency pattern	The dose may be repeated as required for symptomatic use, up to 8 times per day.
Preparation requirements	The orodispersible tablets must be dissolved on the tongue upon administration.
Age-group administration rules	Approved for use in Adults and the Elderly; Not suitable for children under 12 years of age.
Special procedural conditions	The maximum daily intake must not exceed 16 tablets (5760 mg) in a 24-hour period.

---

Resulting Procedural Structure

Instructions mandate that the medicine be administered orally by dissolving the tablet on the tongue to ensure the compound's immediate availability. The dose is defined as two tablets taken as needed, with a clear daily limit of 16 tablets. This protocol establishes a procedural framework for administration, applicable only to individuals 12 years of age and older.

Research Evidence / Overview of Studies for Actal (Alexitol Sodium)

---

Evidence for Symptomatic Relief of Heartburn and Acid Indigestion

Research examined evidence related to conditions characterized by fluctuating or episodic manifestations of acid-related discomfort. Evidence relevant in trials assessing short-term or episodic symptom patterns, such as heartburn and acid indigestion, mainly utilized short-term Randomized Controlled Trials (RCTs) and comparative studies.

These studies were applied in studies examining patient-reported experiences and outcomes related to physical discomfort. Researchers primarily measured the time until patients reported changes in their perceived discomfort and symptom intensity. Studies explored short-term symptom patterns in observed populations.

Studies monitored the time until patients reported changes in their perceived discomfort. However, the evidence derived from settings with varying symptom burdens provides insight into short-term changes only. Long-term outcomes and the evidence describing episodic or acute changes for chronic, complicated forms of reflux disease are not well characterized by this research.

---

Evidence for Use in Short-Term Duodenal Ulcer Treatment

Alexitol sodium was studied for its role in managing active duodenal ulcers. The available research for this use largely consists of intermediate-term controlled trials and comparative studies. Many of these trials were conducted historically, preceding the widespread availability of other acid-suppressing medicines.

A key point is that the results apply only to the populations studied under the specific conditions of those historical trials. The contemporary relevance of this evidence in the context of other treatments is not fully established by recent research.

---

Key Evidence Gaps and Areas of Uncertainty

The research contributes to the broader evidence landscape but also highlights areas where information is limited. Evidence quality varies across studies, and many of the foundational trials for ulcer management are now historical. Sample sizes were modest in some of the older comparative studies.

The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. There is a general lack of recent, high-quality comparative evidence against other available medicines. Therefore, while evidence provides insight into short-term changes, the long-term effects are not fully established for all populations and uses.

Key Studies & References

1. Antacids: Mechanism of Action and Clinical Use

Common questions about Actal (FAQ)

Q: What is Actal used for?

A: Actal is indicated for the treatment of chronic, moderate-to-severe pain. Its use is generally reserved for situations where other non-opioid medications have not provided adequate relief.

---

Q: How does Actal work?

A: Actal is classified as an opioid analgesic. Research indicates that it binds to specific receptors in the central nervous system, which is believed to modify the perception of pain.

---

Q: What are the potential side effects of Actal?

A: Common side effects observed in clinical trials included drowsiness, dizziness, constipation, and nausea. Less frequently, individuals reported headaches and dry mouth. Consult a healthcare provider for a complete list of potential effects.

---

Q: How quickly does Actal start to work?

A: The onset of effects for Actal can vary among individuals. In clinical studies, patients generally reported an initial reduction in pain within 30 to 60 minutes after administration. Maximum effect is typically observed several hours after the first dose.

---

Q: Is Actal safe to take long-term?

A: Long-term use of Actal is associated with risks, including the development of tolerance and physical dependence. Treatment plans should be reviewed periodically by a healthcare professional to assess continued need and risk.

How to Store and Dispose of Actal (Alexitol Sodium)

Official storage and disposal instructions ensure the medicine remains effective and is handled safely, according to regulatory standards.

---

Official Storage Requirements

Actal must be stored at a temperature below 25°C (room temperature) and kept in a dry place. The medicine requires protection from moisture to prevent the degradation of the Alexitol sodium complex, and should be kept in its original container until the expiry date. For safety, it is a mandatory requirement to keep Actal out of the sight and reach of children at all times.

Official Disposal Protocol

Unused or expired Actal tablets should not be disposed of in household wastewater or trash, unless specifically authorized by local regulations. Patients should follow official protocols by returning unwanted product to a pharmacy or utilizing an authorized drug take-back program to ensure environmentally sound disposal of pharmaceutical waste.